• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于临床病例对照研究的预处理循环血清细胞因子与滤泡性和弥漫性大 B 细胞淋巴瘤的关系。

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.

机构信息

Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Cytokine. 2012 Dec;60(3):882-9. doi: 10.1016/j.cyto.2012.08.028. Epub 2012 Sep 23.

DOI:10.1016/j.cyto.2012.08.028
PMID:23010502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3483382/
Abstract

BACKGROUND

Abnormal immune function is a key factor in predisposition to non-Hodgkin lymphoma (NHL). We evaluated the association of 30 cytokines individually and as a profile with diffuse large B-cell (DLBCL) and follicular (FL) lymphomas.

METHODS

We used a multiplexed assay to measure 30 cytokine concentrations in pre-treatment serum in a case-control study of 234 FL, 188 DLBCL, and 400 control participants. Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for age and sex, and polytomous regression was used to evaluate heterogeneity between FL and DLBCL. Principal components analysis (PCA) was used to assess cytokine profiles associated with FL and DLBCL.

RESULTS

In single cytokine modeling, we found that 12 of the 30 circulating serum cytokines were significantly (P<0.05) associated with FL and/or DLBCL after accounting for multiple testing (q<0.05). Soluble IL-2R (sIL-2R) had the strongest association with both FL (OR=6.0 for highest versus lowest tertile, 95% CI 3.8-9.5; p-trend=1.8 × 10(-21)) and DLBCL (OR=7.6, 95% CI 4.5-13.1; p-trend=7.2 × 10(-20)). IL1RA and IL-12p40 also showed similar associations for DLBCL and FL. In contrast, HGF, MIG, and MIP-1α had a stronger association with DLBCL compared to FL, and IL-6, IL-8, IL-10, IFN-γ, IP-10, and VEGF were only statistically significantly associated with DLBCL after accounting for multiple testing. However, in PCA modeling, a cytokine profile based on sIL-2R, IL-1RA, MIG, IP-10, IL-8, and IL-12p40 explained most of the variability between controls and both FL and DLBCL.

CONCLUSIONS

We identified some cytokines unique to DLBCL, but overall cytokine associations were more similar than distinct for DLBCL and FL. While these data are limited by concerns of reverse causality, they do suggest cytokines and cytokine profiles that can be prioritized in future studies.

摘要

背景

异常的免疫功能是非霍奇金淋巴瘤(NHL)易感性的一个关键因素。我们评估了 30 种细胞因子单独作为一个谱与弥漫性大 B 细胞(DLBCL)和滤泡性(FL)淋巴瘤的关联。

方法

我们使用一种多重分析方法来测量 234 例 FL、188 例 DLBCL 和 400 例对照参与者治疗前血清中的 30 种细胞因子浓度。使用条件逻辑回归估计调整年龄和性别后的比值比(OR)和 95%置信区间(CI),并使用多元回归评估 FL 和 DLBCL 之间的异质性。主成分分析(PCA)用于评估与 FL 和 DLBCL 相关的细胞因子谱。

结果

在单细胞因子建模中,我们发现 30 种循环血清细胞因子中有 12 种在考虑到多次检验(q<0.05)后与 FL 和/或 DLBCL 显著相关(P<0.05)。可溶性白细胞介素-2 受体(sIL-2R)与 FL(最高与最低三分位组的比值比[OR]为 6.0,95%CI 为 3.8-9.5;p 趋势=1.8×10(-21))和 DLBCL(OR 为 7.6,95%CI 为 4.5-13.1;p 趋势=7.2×10(-20))均有最强的关联。IL1RA 和 IL-12p40 也与 DLBCL 和 FL 有类似的关联。相比之下,HGF、MIG 和 MIP-1α 与 DLBCL 的关联强于 FL,而 IL-6、IL-8、IL-10、IFN-γ、IP-10 和 VEGF 仅在考虑到多次检验后才与 DLBCL 有统计学显著关联。然而,在 PCA 建模中,基于 sIL-2R、IL-1RA、MIG、IP-10、IL-8 和 IL-12p40 的细胞因子谱解释了对照组与 FL 和 DLBCL 之间的大部分可变性。

结论

我们确定了一些与 DLBCL 独特相关的细胞因子,但总的来说,DLBCL 和 FL 的细胞因子关联更相似而不是不同。尽管这些数据受到反向因果关系的限制,但它们确实表明可以在未来的研究中优先考虑细胞因子和细胞因子谱。

相似文献

1
Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.基于临床病例对照研究的预处理循环血清细胞因子与滤泡性和弥漫性大 B 细胞淋巴瘤的关系。
Cytokine. 2012 Dec;60(3):882-9. doi: 10.1016/j.cyto.2012.08.028. Epub 2012 Sep 23.
2
Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study.基于人群的病例对照研究中,组织学和 t(14;18)定义的非霍奇金淋巴瘤亚型的危险因素。
Int J Cancer. 2011 Aug 15;129(4):938-47. doi: 10.1002/ijc.25717. Epub 2010 Nov 23.
3
Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.非霍奇金淋巴瘤:利妥昔单抗对弥漫性大 B 细胞淋巴瘤和滤泡性淋巴瘤患者总生存的影响。
Arch Med Res. 2015 Aug;46(6):454-61. doi: 10.1016/j.arcmed.2015.07.004. Epub 2015 Jul 31.
4
Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.外周血淋巴细胞/单核细胞比值可预测利妥昔单抗时代滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤患者的预后。
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):208-13. doi: 10.1016/j.clml.2014.10.001. Epub 2014 Oct 23.
5
Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.先天免疫系统中模式识别基因的多态性与非霍奇金淋巴瘤的风险。
Environ Mol Mutagen. 2013 Jan;54(1):72-7. doi: 10.1002/em.21739. Epub 2012 Oct 11.
6
Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study.生殖因素、绝经激素治疗与非霍奇金弥漫大 B 细胞淋巴瘤和滤泡性淋巴瘤风险:一项英国病例对照研究。
Cancer Causes Control. 2010 Dec;21(12):2079-83. doi: 10.1007/s10552-010-9626-2. Epub 2010 Aug 10.
7
Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.循环免疫标志物与非霍奇金淋巴瘤亚型风险:一项汇总分析。
Int J Cancer. 2023 Mar 1;152(5):865-878. doi: 10.1002/ijc.34299. Epub 2022 Oct 5.
8
Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.胚系变异在滤泡性和弥漫性大 B 细胞淋巴瘤中的补体基因与无事件生存。
Am J Hematol. 2012 Sep;87(9):880-5. doi: 10.1002/ajh.23273. Epub 2012 Jun 20.
9
Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study.脂类表型变异与非霍奇金淋巴瘤亚型风险:一项孟德尔随机化研究。
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):1074-1078. doi: 10.1158/1055-9965.EPI-19-0803. Epub 2020 Feb 27.
10
Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.可溶性 B 细胞激活免疫标志物对人体测量学和生活方式因素与淋巴瘤发展之间关联的中介效应。
Sci Rep. 2020 Aug 14;10(1):13814. doi: 10.1038/s41598-020-70790-9.

引用本文的文献

1
Elevated serum IL-10/IL-6 ratio as a novel biomarker for secondary central nervous system lymphoma and poor prognosis in DLBCL.血清IL-10/IL-6比值升高作为弥漫性大B细胞淋巴瘤继发中枢神经系统淋巴瘤及预后不良的一种新型生物标志物。
Front Immunol. 2025 Aug 13;16:1656044. doi: 10.3389/fimmu.2025.1656044. eCollection 2025.
2
Body Composition in Patients with Follicular Lymphoma: Asso-Ciations between Changes in Radiomic Parameters in Patients Treated with R-CHOP-like and R-B Regimens: LyRa 01F.滤泡性淋巴瘤患者的身体组成:接受类似R-CHOP和R-B方案治疗患者的影像组学参数变化之间的关联:LyRa 01F研究
Cancers (Basel). 2023 Feb 4;15(4):999. doi: 10.3390/cancers15040999.
3
Two cases of axillary lymphadenopathy diagnosed as diffuse large B-cell lymphoma developed shortly after BNT162b2 COVID-19 vaccination.两例被诊断为弥漫性大B细胞淋巴瘤的腋窝淋巴结病在接种BNT162b2新冠疫苗后不久出现。
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e613-e615. doi: 10.1111/jdv.18136. Epub 2022 Apr 18.
4
Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.非经典单核细胞易于迁移至弥漫性大 B 细胞淋巴瘤肿瘤中。
Front Immunol. 2021 Dec 16;12:755623. doi: 10.3389/fimmu.2021.755623. eCollection 2021.
5
Tear cytokine profiles in patients with extranodal marginal zone B-cell lymphoma of the ocular adnexa.眼附属器结外边缘区 B 细胞淋巴瘤患者的泪液细胞因子谱。
Eye (Lond). 2022 Jul;36(7):1396-1402. doi: 10.1038/s41433-021-01650-7. Epub 2021 Jun 28.
6
Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy.弥漫性大B细胞淋巴瘤患者化疗期间外周血淋巴细胞亚群计数及功能的动态变化
Cancer Cell Int. 2021 May 27;21(1):282. doi: 10.1186/s12935-021-01978-w.
7
Circulating Myeloid Regulatory Cells: Promising Biomarkers in B-Cell Lymphomas.循环髓系调节细胞:B 细胞淋巴瘤有前途的生物标志物。
Front Immunol. 2021 Feb 2;11:623993. doi: 10.3389/fimmu.2020.623993. eCollection 2020.
8
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.肿瘤干扰素信号和抑制性髓系细胞与大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞治疗失败相关。
Blood. 2021 May 13;137(19):2621-2633. doi: 10.1182/blood.2020007445.
9
Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine.髓源性抑制细胞免疫抑制机制:白细胞介素-10 作为关键免疫调节细胞因子的作用。
Open Biol. 2020 Sep;10(9):200111. doi: 10.1098/rsob.200111. Epub 2020 Sep 16.
10
Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen.血清白细胞介素-18水平和可溶性白细胞介素-2受体对接受R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者临床结局的影响。
Future Sci OA. 2019 Aug 28;5(9):FSO414. doi: 10.2144/fsoa-2019-0076.

本文引用的文献

1
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.血清干扰素诱导蛋白-10(CXCL10)水平升高可预测弥漫大 B 细胞淋巴瘤患者的疾病复发和预后。
Am J Hematol. 2012 Sep;87(9):865-9. doi: 10.1002/ajh.23259. Epub 2012 Jun 3.
2
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.IL-12 上调 TIM-3 的表达并诱导滤泡性 B 细胞非霍奇金淋巴瘤患者 T 细胞耗竭。
J Clin Invest. 2012 Apr;122(4):1271-82. doi: 10.1172/JCI59806. Epub 2012 Mar 19.
3
Circulating cytokine levels, Epstein-Barr viremia, and risk of acquired immunodeficiency syndrome-related non-Hodgkin lymphoma.循环细胞因子水平、Epstein-Barr 病毒血症与获得性免疫缺陷综合征相关非霍奇金淋巴瘤风险。
Am J Hematol. 2011 Oct;86(10):875-8. doi: 10.1002/ajh.22119.
4
Follicular lymphoma: 2011 update on diagnosis and management.滤泡性淋巴瘤:诊断与治疗的 2011 年更新。
Am J Hematol. 2011 Sep;86(9):768-75. doi: 10.1002/ajh.22099.
5
Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.可溶性白细胞介素 2 受体α促进白细胞介素 2 介导的免疫应答,并预测滤泡 B 细胞非霍奇金淋巴瘤患者的生存时间缩短。
Blood. 2011 Sep 8;118(10):2809-20. doi: 10.1182/blood-2011-03-340885. Epub 2011 Jun 30.
6
Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma.一项基于诊所的淋巴瘤分子流行病学病例对照研究的设计与效度
Int J Mol Epidemiol Genet. 2011;2(2):95-113. Epub 2011 Apr 5.
7
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.癌症统计数据,2011 年:消除社会经济和种族差异对癌症过早死亡的影响。
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17.
8
Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.诊断前血清细胞因子和其他免疫标志物水平与非霍奇金淋巴瘤风险。
Cancer Res. 2011 Jul 15;71(14):4898-907. doi: 10.1158/0008-5472.CAN-11-0165. Epub 2011 Jun 1.
9
B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.B 细胞刺激细胞因子和免疫激活标志物在系统性艾滋病相关非霍奇金 B 细胞淋巴瘤诊断前几年就升高了。
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1303-14. doi: 10.1158/1055-9965.EPI-11-0037. Epub 2011 Apr 28.
10
The challenge of the microenvironment in B-cell lymphomas.B 细胞淋巴瘤微环境的挑战。
Histopathology. 2011 Jan;58(1):69-80. doi: 10.1111/j.1365-2559.2010.03706.x.